Traditional HIV therapy involves a drug cocktail of three drugs that attack various stages of the HIV lifecycle. More recently, a new class of drugs was discovered that prevents the entry of viruses into immune cells. Co-receptor inhibitors play a crucial role in preventing viral activation by interfering with the initial binding to CCR5 and CXCR4. There has only been one FDA-approved CCR5 inhibitor, maraviroc, which exhibits efficacy against HIV strains that are resistant to reverse transcriptase and protease inhibitors. While maraviroc is effective against CCR5-viruses, it has limitations against the CXCR4 receptor which is an important receptor in the progression of the infection. Therefore, further research is needed to provide more effective entry inhibitors as alternative medicines for HIV treatment. The goal of this project is to design and synthesize dual CCR5/CXCR4 inhibitors in our lab. Using a computational screen, our lab has identified a compound that is predicted to bind to both CCR5 and CXCR4. An initial target for synthesis was the analog of the screened compound using the commercially available and cost-effective adenosine. Our synthetic strategy involved the coupling of a carboxylic acid-containing modified adenosine fragment with an amine-containing peptide fragment. Although the target compound was synthesized, its isolation proved challenging due to the presence of many impurities. As such, an alternative approach has been explored with ribavirin instead of adenosine. Ribavirin is an FDA-approved medication in the treatment of hepatitis C virus, which is an opportunistic infection for HIV patients. Preparation of the carboxylic acid-containing ribavirin fragment was hampered by the difficult oxidation step due in part to the hydrophilicity of the desired product. Analogues of the amine-containing fragment were also pursued by replacing the original phenylalanine with valine.